Clinuvel Pharmaceuticals (AU:CUV)
A$7.59+0.17 (+2.29%)
AU:CUV
Clinuvel Pharmaceuticals financials statements
A$7.59
At close:+0.17 (+2.29%)
Want to see AU:CUV full AI Analyst Report?
Clinuvel Pharmaceuticals (CUV) Ratios
118 Followers
Clinuvel Pharmaceuticals Ratios
AU:CUV's free cash flow for Q4 2026 was AU$22.93M. For the 2026 fiscal year, AU:CUV's free cash flow was decreased by AU$-1.45M and operating cash flow was AU$24.38M. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 14.81 | 9.66 | 8.81 | 7.44 | 10.24 |
| Quick Ratio | 14.45 | 9.34 | 8.39 | 7.06 | 10.10 |
| Cash Ratio | 1.06 | 8.24 | 7.29 | 0.94 | 2.00 |
| Solvency Ratio | 1.50 | 1.21 | 1.31 | 1.05 | 1.12 |
| Operating Cash Flow Ratio | 1.92 | 1.51 | 1.47 | 1.45 | 2.90 |
| Short-Term Operating Cash Flow Coverage | 94.98 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | AU$ 261.36M | AU$ 232.03M | AU$ 193.95M | AU$ 159.72M | AU$ 121.33M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.13 | 1.14 | 1.18 | 1.15 |
| Debt Service Coverage Ratio | 59.11 | 9.37 | 9.26 | 9.83 | 9.51 |
| Interest Coverage Ratio | 498.67 | 10.25 | 10.78 | 12.81 | 14.55 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.04 | 0.10 | 0.10 | 0.08 | 0.07 |
| Net Debt to EBITDA | -0.45 | -3.91 | -3.25 | -0.49 | -0.75 |
| Profitability Margins | |||||
| Gross Profit Margin | 83.18% | 83.29% | 91.23% | 64.59% | 70.93% |
| EBIT Margin | 43.11% | 58.95% | 62.52% | 62.27% | 55.68% |
| EBITDA Margin | 44.16% | 60.20% | 63.82% | 59.20% | 53.37% |
| Operating Profit Margin | 43.11% | 48.13% | 54.44% | 52.23% | 50.34% |
| Pretax Profit Margin | 50.69% | 54.26% | 57.47% | 58.19% | 52.22% |
| Net Profit Margin | 36.07% | 38.07% | 40.41% | 39.08% | 31.77% |
| Continuous Operations Profit Margin | 36.07% | 38.07% | 40.41% | 39.08% | 31.77% |
| Net Income Per EBT | 71.16% | 70.17% | 70.32% | 67.15% | 60.83% |
| EBT Per EBIT | 117.59% | 112.73% | 105.57% | 111.41% | 103.74% |
| Return on Assets (ROA) | 11.45% | 13.31% | 15.42% | 15.73% | 14.42% |
| Return on Equity (ROE) | 12.43% | 15.02% | 17.55% | 18.59% | 16.63% |
| Return on Capital Employed (ROCE) | 14.64% | 18.70% | 23.31% | 24.20% | 25.24% |
| Return on Invested Capital (ROIC) | 10.40% | 13.10% | 16.36% | 16.22% | 15.32% |
| Return on Tangible Assets | 11.46% | 13.32% | 15.43% | 15.76% | 14.45% |
| Earnings Yield | 6.61% | 6.96% | 4.57% | 3.46% | 2.85% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.01 | 3.46 | 3.36 | 3.53 | 4.06 |
| Payables Turnover | 12.36 | 6.23 | 3.30 | 9.93 | 73.71 |
| Inventory Turnover | 2.30 | 1.80 | 0.73 | 2.91 | 10.43 |
| Fixed Asset Turnover | 10.17 | 13.33 | 11.42 | 27.47 | 24.34 |
| Asset Turnover | 0.32 | 0.35 | 0.38 | 0.40 | 0.45 |
| Working Capital Turnover Ratio | 0.38 | 0.44 | 0.49 | 0.54 | 0.59 |
| Cash Conversion Cycle | 220.35 | 249.62 | 499.48 | 192.08 | 120.03 |
| Days of Sales Outstanding | 91.05 | 105.49 | 108.61 | 103.53 | 89.98 |
| Days of Inventory Outstanding | 158.83 | 202.75 | 501.57 | 125.29 | 35.00 |
| Days of Payables Outstanding | 29.53 | 58.62 | 110.70 | 36.74 | 4.95 |
| Operating Cycle | 249.88 | 308.24 | 610.18 | 228.82 | 124.98 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.74 | 0.82 | 0.73 | 0.75 | 0.81 |
| Free Cash Flow Per Share | 0.71 | 0.81 | 0.62 | 0.73 | 0.80 |
| Dividend Paid and CapEx Coverage Ratio | 8.99 | 14.66 | 4.61 | 12.29 | 23.88 |
| Capital Expenditure Coverage Ratio | 23.04 | 137.64 | 6.64 | 35.92 | 91.78 |
| Operating Cash Flow Coverage Ratio | 19.04 | 77.75 | 42.12 | 36.92 | 31.73 |
| Operating Cash Flow to Sales Ratio | 0.39 | 0.43 | 0.42 | 0.47 | 0.61 |
| Free Cash Flow Yield | 6.89% | 7.85% | 4.04% | 4.06% | 5.37% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 15.12 | 14.42 | 21.88 | 28.87 | 35.14 |
| Price-to-Sales (P/S) Ratio | 5.45 | 5.47 | 8.84 | 11.28 | 11.16 |
| Price-to-Book (P/B) Ratio | 1.88 | 2.16 | 3.84 | 5.37 | 5.84 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 14.52 | 12.74 | 24.77 | 24.62 | 18.61 |
| Price-to-Operating Cash Flow Ratio | 13.89 | 12.65 | 21.04 | 23.93 | 18.40 |
| Price-to-Earnings Growth (PEG) Ratio | -2.72 | 5.05 | 1.36 | 0.61 | -2.20 |
| Enterprise Value Multiple | 11.90 | 5.18 | 10.60 | 18.56 | 20.17 |
| Enterprise Value | 494.25M | 296.21M | 596.62M | 860.59M | 707.59M |
| EV to EBITDA | 11.90 | 5.18 | 10.60 | 18.56 | 20.17 |
| EV to Sales | 5.26 | 3.12 | 6.77 | 10.99 | 10.77 |
| EV to Free Cash Flow | 14.00 | 7.26 | 18.95 | 23.98 | 17.94 |
| EV to Operating Cash Flow | 13.39 | 7.21 | 16.10 | 23.31 | 17.75 |
| Tangible Book Value Per Share | 5.47 | 4.81 | 3.97 | 3.32 | 2.53 |
| Shareholders’ Equity Per Share | 5.47 | 4.81 | 3.98 | 3.33 | 2.54 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.29 | 0.30 | 0.30 | 0.33 | 0.39 |
| Revenue Per Share | 1.89 | 1.90 | 1.73 | 1.59 | 1.33 |
| Net Income Per Share | 0.68 | 0.72 | 0.70 | 0.62 | 0.42 |
| Tax Burden | 0.71 | 0.70 | 0.70 | 0.67 | 0.61 |
| Interest Burden | 1.18 | 0.92 | 0.92 | 0.93 | 0.94 |
| Research & Development to Revenue | 0.19 | 0.08 | 0.03 | 0.02 | 0.02 |
| SG&A to Revenue | 0.21 | 0.28 | 0.02 | 0.02 | 0.02 |
| Stock-Based Compensation to Revenue | 0.00 | 0.02 | 0.07 | 0.11 | 0.09 |
| Income Quality | 1.09 | 1.14 | 1.04 | 1.21 | 1.91 |
Currency in AUD

